跳至主要内容
临床试验/ACTRN12617000402347
ACTRN12617000402347招募中未知

Endoscopic ablation of dysplastic Barrett’s oesophagus

Royal Prince Alfred Hospital0 个研究点目标入组 20 人开始时间: 2017年3月17日最近更新:

试验速览

阶段
未知
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • Barrett's oesophagus with low grade dysplasia, high grade dysplasia or T1a adenocarcinoma

排除标准

  • a)C value greater than 6 cm using the Prague criteria
  • b)Prior ER for adenocarcinoma with histological diagnosis of greater than or equal to T1b;
  • c)Presence of endoscopically visible abnormalities at the time of initial APC treatment (additional endoscopic resection is allowed);
  • d)Presence of cancer in random biopsies obtained at the mapping endoscopy, 8-12 weeks before initial HAPC treatment without endoscopic resection of cancer lesion for staging;
  • e)Pregnancy
  • f)Patients in whom complete eradication is not considered a relevant treatment goal or in whom additional treatment is contraindicated;
  • g)Patients with incomplete healing post-endoscopic resection despite adequate PPI-medication;
  • h)Prior ablative therapy in the oesophagus;
  • i)Significant oesophageal stenosis prior to initial HAPC treatment defined as a stenosis that cannot be passed by a therapeutic endoscope or a stenosis that has been dilated endoscopically before.
  • j)Presence of esophageal varices
  • k)Anticoagulant therapy (apart from aspirin or NSAIDS) that cannot be discontinued prior to HAPC or incorrectable hemostatic disorders
  • l)Life expectancy less than 2 years

研究者

相似试验